By Vvon Engineering Team | Published | Updated
Clinical readiness, product supply, activity measurement, shielding, patient pathways, imaging and authorised waste arrangements to assess before adding a Lu-177 service.
Nuclear medicine RFQ checklist (TXT)
A Lu-177 therapy service requires an authorised clinical programme, appropriately trained staff, reliable product supply, suitable administration and observation facilities, and a radiation-protection and waste plan. Camera capability is one part of that assessment, not proof that the service is ready.
Lutetium-177 has a physical half-life of approximately 6.65 days, which permits different delivery arrangements from short-lived diagnostic tracers. Product expiry, radiochemical stability, calibration time, import permissions and actual transport still constrain use. A delayed consignment can disrupt a treatment even when measurable activity remains.
Three things still have to be arranged rather than assumed. The consignment is calibrated for a date and time, so the activity that arrives has to be assayed on receipt and reconciled with the certificate. Customs clearance has to be predictable, which means the import documentation and the regulatory authorisations are in place before the first order rather than during it. And the delivery has to be met: a therapy consignment sitting in a cargo shed over a weekend is both a loss and a regulatory problem. The general discipline is in radiopharmaceutical supply and logistics, and the packaging and paperwork on the road leg are in moving radioactive material by road.
Lu-177-labelled somatostatin and PSMA-targeted products support defined treatment indications in relevant jurisdictions. Eligibility, product authorisation, cycle planning and clinical management must follow the applicable approved product and specialist protocol. Forecast appointments by planned treatment cycles, including assessment and follow-up.
Assess whether administration can be outpatient or requires inpatient care under the local authorisation and clinical pathway. Plan suitable observation, toilets, contamination control, emergency access and nursing arrangements. A separate ward bed is not a universal prerequisite for every Lu-177 service.
The room and release arrangements depend on the radiopharmaceutical, activity, patient condition and household circumstances as well as local requirements. Neither I-131 nor Lu-177 always implies a fixed inpatient stay. Confirm BAERA requirements and the institution's clinical and radiation-protection plan before offering treatment.
| Element | What a diagnostic department already has | What a Lu-177 service adds |
|---|---|---|
| Imaging | Gamma camera or SPECT/CT with the usual protocols | Quantitative reconstruction, attenuation correction and camera time for post-therapy imaging |
| Hot lab | Existing diagnostic equipment may provide some functions | Validate activity measurement, shielding and administration equipment for the exact product and geometry |
| Patient area | Facilities suitable for the existing authorised service | Assess administration, observation, toilets and outpatient/inpatient requirements for the approved pathway |
| Waste | Existing streams and authorised routes | Assess quantities, retention and long-lived impurities; not all diagnostic waste has a six-hour half-life |
| Records | Authorised diagnostic records | Product, prescription, activity, imaging/dosimetry where required, release assessment and treatment history |
Lutetium 177 is a beta emitter with gamma emissions useful enough to image. That combination changes the shielding at the bench in a way that catches out people whose instinct is that more lead is always better.
Shielding for beta and gamma emitters must consider the emission spectrum, bremsstrahlung, activity and geometry. A low-Z inner layer can be useful for some beta sources, but a layered acrylic/tungsten arrangement is not a universal Lu-177 requirement. The physicist and manufacturer should select and verify the shielding for the intended handling task.
Nuclear Shields lists beta and dual beta/gamma syringe-shield designs. Select an isotope-rated configuration that fits the syringe and intended procedure; a catalogue description does not establish the optimum staff-dose reduction for a treatment. Do not assume that thick tungsten necessarily increases hand dose or that an acrylic shield alone covers Lu-177 gamma emissions.
The administration itself is usually an infusion rather than a bolus, which introduces a line, a pump and a set of tubing that all become contaminated. Plan for shielding around the infusion, for a defined route from the hot lab to the bedside, and for what happens to the giving set afterwards. That last item is a surprisingly large fraction of the waste volume.
Size decay storage using the radionuclides and impurities, waste volume and authorised clearance route. Short-lived technetium waste is not automatically clear the following day. Lu-177 waste may require substantially longer storage, and products containing long-lived Lu-177m impurity need specific consideration. Obtain the product radionuclidic information before finalising the waste plan.
Work out the store from the arithmetic rather than the floor plan: volume per cycle, multiplied by cycles per month, multiplied by the number of months the waste has to sit before it can be cleared. That product is the internal volume the decay store has to have, and it is usually several times what a department expects. Nuclear Shields supply shielded waste bins from 18 to 80 litres in 3 and 6 mm of lead, mobile bins in 12 and 25 mm with pedal lids and castors, shielded sharps bins with replaceable plastic inserts, and shielded decay containers and decay caves for the store itself. The segregation and record keeping side is set out in radioactive waste in a nuclear medicine department.
Patient excreta can be an important release pathway, with the fraction and timing dependent on the product and patient. Agree the authorised drainage and contamination-control arrangements at design stage. Delay tanks are not a universal requirement and must not be added or omitted without the applicable assessment.
Patient-specific dosimetry estimates absorbed dose from quantitative measurements and an appropriate model. Requirements vary with the product, protocol and research or clinical purpose. Where dosimetry is planned, specify image calibration, time points, segmentation, uncertainty and staff expertise before purchasing software.
Doing that properly requires three things from the imaging side. The camera has to reconstruct quantitatively, with attenuation and scatter correction, so that a voxel value means an activity concentration rather than a shade of grey. The camera has to be cross-calibrated against the dose calibrator, because the whole chain is anchored on the measurement of what was administered. And the department has to give up camera slots: each imaging time point is an acquisition, and a service treating several patients a cycle can find dosimetry consuming a meaningful share of the diagnostic list. Count that cost honestly at planning stage.
For a dosimetry enquiry, confirm isotope support, quantitative calibration, attenuation and scatter correction, required acquisitions and the exact software licence. Detector technology or a named correction package alone does not create a validated absorbed-dose result. Compare manufacturer-supported configurations on the intended workflow.
Use the patient-release assessment required by the local authorisation and clinical protocol. This may involve measured dose rate and other factors; neither a single reading nor administered activity alone universally determines suitability for release. Record the method, result and responsible decision.
What happens next is a household problem rather than a hospital one, and it is where Bangladeshi departments have to work harder than the textbooks assume. The instructions cover sleeping arrangements, toilet use and flushing, laundry, close contact with children and pregnant women, and how long each restriction lasts. For them to be followed they have to be written in Bangla, they have to be explained to the family member who will actually run the household, and they have to be handed over as a document rather than said at a busy discharge desk. Give the patient a card they can show if they set off a monitor at an airport or a port, and give the department's telephone number to a person who will answer it.
Agree clinical authorisation, facilities, product supply, waste arrangements and staffing as coordinated project workstreams. If patient-specific dosimetry is required for the proposed practice, include it before clinical use rather than defer it automatically to a later phase.
Send Vvon the proposed clinical equipment scope, isotope and product details, expected cycle workload and floor plan. We can discuss imaging, shielding and waste-equipment options in the catalogue. Confirm current product compatibility, site responsibilities and service terms in writing; clinical and regulatory authorisation remain with the responsible institution and authorities. Contact +8801805987890 or info@vvon.com.bd.
Share your application, equipment requirements and procurement timeline. Our engineers can help clarify the configuration and scope for your enquiry.